Pointe Capital Management LLC Takes Position in Stryker Corporation $SYK

Pointe Capital Management LLC acquired a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 1,594 shares of the medical technology company’s stock, valued at approximately $502,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter worth $27,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $27,000. Finally, Gables Capital Management Inc. purchased a new stake in shares of Stryker during the second quarter valued at $25,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock opened at $331.06 on Wednesday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $126.98 billion, a PE ratio of 34.31, a price-to-earnings-growth ratio of 2.09 and a beta of 0.76. The business has a fifty day simple moving average of $327.80 and a 200-day simple moving average of $331.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 355,370 shares of company stock worth $119,447,201 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SYK. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Barclays reduced their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a report on Friday, May 1st. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.